| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000044180 |
| Receipt No. | R000050454 |
| Scientific Title | Efficacy of brolucizumab on AMD in patients exhibiting aflibercept resistance |
| Date of disclosure of the study information | 2021/05/12 |
| Last modified on | 2021/05/12 (Ver. 1) |
| Basic information | ||
| Public title | Efficacy of brolucizumab on AMD in patients exhibiting
aflibercept resistance |
|
| Acronym | AMD treated by anti-VEGF drugs | |
| Scientific Title | Efficacy of brolucizumab on AMD in patients exhibiting
aflibercept resistance |
|
| Scientific Title:Acronym | AMD treated by anti-VEGF drugs | |
| Region |
|
|
| Condition | ||
| Condition | AMD | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine outcomes of the switch to brolucizumab in neovascular age-related macular degeneration (nAMD) refractory to aflibercept. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Sex, age, visual acuity, visual field, refraction, corneal curvature radius, corneal thickness, ocular axial length, fundus observation,Optical coherence tomography, optical coherence tomography angiography, fundus photograph, fluorescence fundus angiography, slit lamp microscopy, duration of disease, current medical history, past history, family history, medication used, frequency of dosing |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with nAMD switched from aflibercept to brolucizumab between June 2020 to December 2020 at Nagoya University Hospital. | |||
| Key exclusion criteria | nothing special | |||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Nagoya University Hospital | ||||||
| Division name | Department of Ophthalmology | ||||||
| Zip code | 466-8560 | ||||||
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya | ||||||
| TEL | 052-744-2275 | ||||||
| takeuchi.jun@med.nagoya-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Nagoya University Hospital | ||||||
| Division name | Department of Ophthalmology | ||||||
| Zip code | 466-8560 | ||||||
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya | ||||||
| TEL | 052-744-2275 | ||||||
| Homepage URL | |||||||
| takeuchi.jun@med.nagoya-u.ac.jp | |||||||
| Sponsor | |
| Institute | Nagoya University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nagoya University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Medical Research and Clinical Ethics Promotion Office |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya |
| Tel | 0527442423 |
| iga-shinsa@adm.nagoya-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | Nagoya University |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | nothing special |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050454 |